A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in
combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR
positive and Her2 negative recurrent/metastatic breast cancer and have received prior
endocrine therapy are eligible for study.